Demystifying Idiopathic Pulmonary Fibrosis

Overview

Prevalence of IPF Age and Gender

IPF in Medicare Beneficiaries

IPF in Medicare Beneficiaries

Defining IPF

Types of UIP Patterns

HRCT Criteria for UIP Pattern

HRCT Images of UIP Patterns Fibrosis

HRCT Criteria for Possible UIP

HRCT Possible UIP Pattern

HRCT Criteria for “Inconsistent With UIP Pattern”

Diagnosing IPF Based on HRCT and Histopathology Findings

Accurate Diagnosis of IPF Summary

Chronic Hypersensitivity Pneumonitis in Patients With Diagnosis of IPF

2011 Evidence-based Guidelines for The Treatment of IPF

2011 Evidence-based Guidelines

Prednisone, Azathioprine, and N-Acetylcysteine for IPF

Results of PANTHER-IPF Trial

Results of a Randomized, Placebo-controlled Trial of Warfarin in IPF

Would Anti-Reflux Therapy Benefit Patients With IPF?

Anti-Reflux Therapy for IPF

Recent Clinical Trials of Endothelin Receptor Antagonists in IPF

Pirfenidone (Investigational)

Nintedanib (Investigational)

Nintedanib (cont)

Results of 3 Completed Phase 3 Trials To Be Presented at 2014 ATS

Co-Trimoxazole

Additional Clinical Trials

Treatment of Comorbidities Also Important in IPF

Preventive Measures

How Standard of Care Has Improved

How Standard of Care Has Improved (cont)

Abbreviations

Abbreviations (cont)

References

References (cont)

References (cont)

References (cont)